Adocia, a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced the establishment of a first proof of concept on its AdoShell Islets implant by having obtained glycemic control without insulin injection in immunocompetent diabetic rats during the 132 days of the study.“Adocia's results are remarkable, having succeeded in the first islet of Langerhans transplant that does not require immunosuppressants in immunocompetent animals.We are delighted to actively participate in this world premiere.» declares Dr. Karim Bouzakri, Director of the CEED (European Center for the Study of Diabetes).AdoShell Islets is an immunoprotective synthetic biomaterial containing islets of Langerhans.After implantation in diabetic animals, the islets contained in AdoShell secrete insulin in response to the level of glucose present in the blood.The physical barrier formed by the biomaterial makes the implanted cells invisible to the host's immune system while allowing the physiological exchanges necessary for the survival and proper functioning of the islets inside AdoShell to pass.This study consisted of implanting islets of Langerhans from allogeneic rats (Wistar strain) – previously encapsulated in AdoShell – in immunocompetent diabetic rats (Lewis strain).The insulin secreted by the grafted islets was measured for 132 days and no slowing down of secretion was observed throughout the duration of the study.At the end of the experiment, the graft was removed causing the drop in insulinemia, the rise in blood sugar and thus the return of the animal to its diabetic state.At the same time, animals in the control group (diabetic rats that did not receive AdoShell Islets) failed to control their blood sugar levels.Other ongoing studies on diabetic rats with the aim of optimizing the AdoShell technology confirm this initial result: normoglycaemia has been observed in 4 diabetic rats for 80 days (studies still ongoing).Weight gain, which is also an important clinical indicator of good health, shows that the islets encapsulated in AdoShell are working as expected.At the same time, the rats of the control group do not gain weight in accordance with what is observed in diabetic rats.These results will be presented at the Cell Therapy Session of PODD 2022 in Boston in October.“This first proof of concept on diabetic rats validates our AdoShell technology.Our purely physico-chemical and non-biological approach is unique, which makes us confident about the transposition of these results from one species to another.», declares Olivier Soula, Deputy CEO of Adocia.Give priority to treating the most serious cases using donor cellsMore than 40 million people around the world suffer from type 11 diabetes called insulin-dependent: In these patients, the beta cells of the islets of Langerhans, cells that secrete insulin, are destroyed by an autoimmune mechanism .As a result, the patient's survival depends on daily insulin injections.Despite taking insulin, some patients have intensely unstable diabetes characterized in particular by extreme glycemic variability, responsible for repeated and/or severe hypoglycaemia not felt, altering quality of life and aggravating morbidity and mortality.The prognosis of this type of diabetes, described as unstable (“brittle”), is poor, with a mortality rate between 20 and 50% over 5 years depending on the studies2.Unstable diabetes affects approximately 3 out of 1,000 people with insulin-dependent diabetes, which represents 1,000 patients in France and nearly 75,000 worldwide.Cell therapy techniques by replacing cells that have been destroyed exist and consist of injecting the patient with islets of Langerhans taken from donor pancreas.These techniques are practiced in many countries and in 2020, the French High Authority for Health issued a favorable opinion on the inclusion of islet transplantation on the list of procedures that may give rise to reimbursement by Insurance. sickness.However, this technique has a major pitfall because – like any allograft – the transplantation of islets as practiced to date requires the concomitant intake of heavy immunosuppressive treatments in order to avoid the rejection of the grafted cells.These immunosuppressive protocols, the adverse effects of which are widely documented (haematological abnormalities, infections and neoplasias), limit the use of transplantation techniques to patients already on immunosuppressive drugs because they have been transplanted kidneys at the same time.The first application of AdoShell Islets aims to improve these techniques carried out using donor pancreas and specifically targets these so-called “brittle” patients so that they can benefit from them.“Our approach is first and foremost very pragmatic: using donor cells already used in current therapy and following existing protocols.So we hope to make a first treatment available to the most severe diabetic patients as soon as possible.» declares Gérard Soula, Chairman and CEO of Adocia.A technology applicable to other cellular sources with the prospect of treating the greatest numberIn parallel with the development of AdoShell Islets from donor pancreas, Adocia also aims to develop its technology from cell lines, which would ultimately make it possible to overcome the limit on the number of donors and thus treat a many more patients."We are currently working on setting up collaborations with companies that are developing cell lines, with a very ambitious vision: to offer the best cure for diabetes without immunosuppressants," concludes Gérard Soula, Chairman and CEO of Adocia.The AdoShell Islets program will be presented in detail to investors and shareholders, like the rest of the Company's program portfolio, during a conference that will take place virtually on September 20, on the occasion of the publication of the financial results. of the first half of 2022.1 International Diabetes Federation, “around 10% of all people with diabetes” 2 HAS – July 2020 https://www.has-sante.fr/jcms/p_3195137/en/transplantation-d-îles-pancreatiques-rapport-d- technology-assessmentShare the post "Adocia: 1st preclinical proof of concept on AdoShell® Islets for the treatment of type 1 diabetes by cell therapy"Sanofi announced that detailed positive results from the Phase III PRIME clinical trial evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis were presented in a late-breaking session of Congress 2022 of de the European Academy of Dermatology and Venereology (EADV, European Academy of Dermatology and Venereology).Genopole: 5 start-ups in the i-Lab competitionFive Genopole start-ups are awarded in the i-Lab competition.Phagos obtains one of the 10 Grand Prizes of the competition, awarded to the “most promising projects, particularly in terms of sustainable development and societal benefits”.Adlin, Cearitis, Everdye and Standing Ovation win a “National Award”.Valneva and VBI Vaccines announced a partnership for the commercialization and distribution in several European countries of PreHevbri®, the only vaccine (recombinant and adsorbed) with three antigens against hepatitis B that has been authorized in Europe.Apmonia Therapeutics, a biotechnology company developing new therapeutic strategies based on peptide approaches, announced that it has obtained a non-dilutive financing of €2.5 million.This new financing is mainly part of Bpifrance's "Deep Tech Development Aid" scheme.The board of directors of the BioValley France division has announced the appointment of its new general manager, Caroline Dreyer.She will take up her duties on October 1, 2022 and will succeed Mr. Marco Pintore, who will have headed the Division for the past five years.Eurasanté, a center of excellence in the nutrition-health sector in the Hauts-de-France region, is submitting a collegial application submitted this summer for the Call for Expression of Interest "BIOCLUSTER" of the 2030 Health Innovation Plan, the results of which will be experienced this fall.This project brings together all the strengths of the fields of industry, care, research and training gathered around a single place with the aim of stimulating an international Biocluster centered on the prevention and management of chronic diseases.Adocia, a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced the establishment of a first proof of concept on its AdoShell Islets implant by having obtained control of glycaemia without injection of insulin in immunocompetent diabetic rats during the 132 days of the study.Every Monday, our free newsletter